Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP

NCT04575545 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2020-10-05

No results posted yet for this study

Summary

The purpose of the study is to assess seroprevalence of COVID-19 infection in a cohort of HIV + patients and in a cohort of patients taking PrEP by emtricitabine / tenofovir.

Conditions

  • Covid19
  • Virus-HIV

Interventions

DIAGNOSTIC_TEST

Serology test for COVID-19

ELISA test

Sponsors & Collaborators

  • Hôpital Européen Marseille

    lead OTHER

Principal Investigators

  • Patrick PHILIBERT · Hôpital Europeen Marseille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2021-03-31
Completion
2022-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575545 on ClinicalTrials.gov